U.S. Judge Orders Trial For Four China Drug Makers Over Vitamin C Price-fixing
This article was originally published in PharmAsia News
Four Chinese medicine-makers, including Hebei Welcome Pharmaceutical, have been ordered by a U.S. federal judge to stand trial on vitamin C price-fixing charges
You may also be interested in...
COVID-19 has shifted consumer health behaviour towards prevention and general wellbeing. However, finding out what consumers actually want and need is still the essence of good OTC innovation, according to Stada Arzneimittel's new vice president of consumer healthcare product development Steve Makin.
Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.
Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU, not least through increasing costs and impacting device availability.